Limitations for health research with restricted data collection from UK primary care.
Confidentiality
/ legislation & jurisprudence
Data Collection
/ legislation & jurisprudence
Databases, Factual
/ legislation & jurisprudence
Electronic Health Records
/ legislation & jurisprudence
Evidence-Based Medicine
/ legislation & jurisprudence
Feasibility Studies
Humans
Primary Health Care
/ legislation & jurisprudence
Reproducibility of Results
Research Design
/ standards
United Kingdom
bias
electronic health records
pharmacoepidemiology
primary care
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
14
06
2018
revised:
30
11
2018
accepted:
14
02
2019
pubmed:
18
4
2019
medline:
6
5
2020
entrez:
18
4
2019
Statut:
ppublish
Résumé
UK primary care provides a rich data source for research. The impact of proposed data collection restrictions is unknown. This study aimed to assess the impact of restricting the scope of electronic health record (EHR) data collection on the ability to conduct research. The study estimated the consequences of restricted data collection on published Clinical Practice Research Datalink studies from high impact journals or referenced in clinical guidelines. A structured form was used to systematically analyse the extent to which individual studies would have been possible using a database with data collection restrictions in place: (1) retrospective collection of specified diseases only; (2) retrospective collection restricted to a 6- or 12-year period; (3) prospective and retrospective collection restricted to non-sensitive data. Outcomes were categorised as unfeasible (not reproducible without major bias); compromised (feasible with design modification); or unaffected. Overall, 91% studies were compromised with all restrictions in place; 56% studies were unfeasible even with design modification. With restrictions on diseases alone, 74% studies were compromised; 51% were unfeasible. Restricting collection to 6/12 years had a major impact, with 67 and 22% of studies compromised, respectively. Restricting collection of sensitive data had a lesser but marked impact with 10% studies compromised. EHR data collection restrictions can profoundly reduce the capacity for public health research that underpins evidence-based medicine and clinical guidance. National initiatives seeking to collect EHRs should consider the implications of restricting data collection on the ability to address vital public health questions.
Identifiants
pubmed: 30993808
doi: 10.1002/pds.4765
pmc: PMC6618795
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
777-787Informations de copyright
© 2019 Crown Copyright. Pharmacoepidemiology & Drug Safety Published by John Wiley & Sons, Ltd.
Références
Drug Intell Clin Pharm. 1988 Feb;22(2):157-61
pubmed: 3349931
J Public Health (Oxf). 2016 Sep;38(3):552-559
pubmed: 26350481
BMJ. 2015 Nov 11;351:h5441
pubmed: 26560308
Eur J Epidemiol. 2019 Jan;34(1):91-99
pubmed: 30219957
BMJ. 2014 Jul 11;349:g4219
pubmed: 25015137
Epilepsy Res. 2002 Aug;50(3):233-41
pubmed: 12200214
Curr Epidemiol Rep. 2015 Sep 1;2(3):162-171
pubmed: 26576336
Prim Care Diabetes. 2016 Oct;10(5):352-9
pubmed: 27013297
Inform Prim Care. 2004;12(1):49-50
pubmed: 15140353
Circulation. 2012 Aug 28;126(9):1050-7
pubmed: 22837162
Int J Epidemiol. 1996 Apr;25(2):435-42
pubmed: 9119571
BMJ. 2008 Jun 28;336(7659):1475-82
pubmed: 18573856
Annu Rev Public Health. 2016;37:61-81
pubmed: 26667605
BMJ. 2015 Jul 17;351:h3853
pubmed: 26187611
QJM. 2008 Feb;101(2):145-53
pubmed: 18180254
Pharmacoepidemiol Drug Saf. 2008 May;17(5):523-32
pubmed: 18215001
Pharmacoepidemiol Drug Saf. 2019 Jun;28(6):777-787
pubmed: 30993808
CMAJ. 2016 Oct 4;188(14):E342-E351
pubmed: 27455981
Lancet. 1998 Feb 28;351(9103):637-41
pubmed: 9500320
BMJ Open. 2016 Oct 11;6(10):e012785
pubmed: 27729352
BMJ Open. 2016 Jul 13;6(7):e011330
pubmed: 27412104
BMC Psychiatry. 2013 May 10;13:135
pubmed: 23663769
BMC Health Serv Res. 2015 Sep 10;15:367
pubmed: 26359265
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
BMJ. 2008 Aug 28;337:a1227
pubmed: 18755769
J Public Health (Oxf). 2015 Jun;37(2):234-40
pubmed: 25326192
BMJ. 2017 Feb 1;356:j84
pubmed: 28148478
BMJ. 2013 Nov 07;347:f6099
pubmed: 24201164
Inform Prim Care. 2004;12(3):171-7
pubmed: 15606990
J Clin Epidemiol. 2005 Apr;58(4):323-37
pubmed: 15862718
Lancet. 2004 Sep 11-17;364(9438):963-9
pubmed: 15364187
Lancet. 2014 Mar 22;383(9922):1015-6
pubmed: 24656186
Pharmacoepidemiol Drug Saf. 2006 Aug;15(8):555-64
pubmed: 16767799
Thorax. 2015 May;70(5):498-500
pubmed: 25385425
Br J Gen Pract. 2000 Jun;50(455):449-54
pubmed: 10962781
PLoS One. 2012;7(12):e52339
pubmed: 23272239
Br J Cancer. 2014 Feb 4;110(3):584-92
pubmed: 24366304
Br J Clin Pharmacol. 2010 Sep;70(3):429-38
pubmed: 20716244
BMC Health Serv Res. 2017 Apr 26;17(1):304
pubmed: 28446159